Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2019-12-19 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS 2 pages 106.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 20 December 2019 from Cyclopharm Limited to the Australian Securities Exchange. It details the execution of an agreement with Cyclotek and related parties to utilize cyclotron facility assets and expand PET diagnostics business opportunities. The content focuses on operational and strategic collaboration agreements, financial impact estimates, and future business prospects. There are no financial statements, quarterly or annual results, nor is there a mention of a report being attached or published. The document is not a full financial report, earnings release, or regulatory certification. It is a corporate announcement about a business agreement and operational update, fitting best under Capital/Financing Update (CAP) as it relates to business arrangements and potential income streams impacting the company's capital and operations.
2019-12-19 English
CYC Institutional Placement - Premium To Share Price 2 pages 103.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 20 December 2019 from Cyclopharm Limited regarding the successful completion of an institutional share placement of 8.5 million new shares at a premium price, raising $9.775 million. It details the share issue price, the premium to the current share price, the involvement of Karst Peak Capital Limited as a substantial shareholder post-placement, and the intended use of the capital raised. The document is clearly about a capital raising event and share issuance, not a full financial report or earnings release. The length is 3683 characters, which is relatively short and typical for a capital/financing update announcement. There is no indication that this is a full annual or interim report, audit report, or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2019-12-19 English
Appendix 3B 12 pages 228.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to a new issue of securities, application for quotation of additional securities, and agreement. It includes detailed information about the class and number of securities issued, terms of the securities, issue price, purpose of the issue, and compliance with ASX rules. The document also contains calculations related to placement capacity under ASX rules 7.1 and 7.1A. This type of document is a regulatory announcement specific to capital raising and securities issuance, typically filed with the Australian Securities Exchange (ASX). It is not a financial report, earnings release, or management discussion. It is a formal announcement about capital changes and securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed information, not just a brief announcement or a report publication notice, so it is not RPA or RNS. Confidence is high due to the clear presence of securities issuance details and ASX Appendix 3B form references.
2019-12-18 English
Pause in Trading 1 page 110.9KB
Regulatory Filings Classification · 100% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (335 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-18 English
Trading Halt 3 pages 172.0KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Cyclopharm Limited dated 19 December 2019. It specifically states that the company has requested a trading halt pending the release of an announcement related to a material capital raising involving a placement to institutional investors. The text is short (3705 characters) and primarily serves as a notification of the trading halt and the reason behind it, rather than providing detailed financial data or the capital raising details themselves. There is no substantive financial report or analysis included, only an announcement of the trading halt and the forthcoming capital raising announcement. According to the classification rules, such a document is best classified as a Capital/Financing Update (CAP) because it relates to capital raising activities and financing updates, even though it is a trading halt notice pending such an announcement. The document is not a full report, nor is it a regulatory filing or report publication announcement since it contains more than a mere statement of report availability and is focused on capital raising. Therefore, the most appropriate classification is CAP with high confidence.
2019-12-18 English
Appendix 3B 13 pages 782.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of shares issued, terms of the securities, issue price, purpose of the issue, and application for quotation of additional securities on the ASX. It references specific ASX rules (Rule 2.7, 3.10.3, 3.10.4, 3.10.5) and includes calculations related to placement capacity under ASX Listing Rules 7.1 and 7.1A. The document is a formal announcement of a new share issue and application for quotation rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the securities issued. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2019-12-11 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.